0.00Open4.00Pre Close0 Volume488 Open Interest230.00Strike Price0.00Turnover38.53%IV5.73%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry4.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3082Delta0.0146Gamma47.95Leverage Ratio-0.1631Theta-0.0486Rho-14.78Eff Leverage0.2212Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet